Logo

PharmaShots Weekly Snapshots (March 21 - 25, 2022)

Share this
PharmaShots Weekly Snapshots (March 21 - 25, 2022)

PharmaShots Weekly Snapshots (March 21 - 25, 2022)

LEO Pharma Presents 3.5 Year Interim Safety & Efficacy Data in P-III (ECZTEND) Trial of Adbry (tralokinumab-ldrm) for Atopic Dermatitis at AAD 2022

Published: Mar 25, 2022 | Tags: LEO Pharma, P-III, ECZTEND Trial, Adbry, tralokinumab-ldrm, Atopic Dermatitis, AAD 2022

Janssen’s Cabenuva (rilpivirine and cabotegravir) Receives the US FDA’s Label Update Approval for the Treatment of HIV

Published: Mar 25, 2022 | Tags: Janssen, Cabenuva, rilpivirine, cabotegravir, US, FDA, Label Update, Approval, HIV

Medtronic Reports the First Patient Implant in (TITAN 2) Study of Implantable Tibial Neuromodulation Device for Overactive Bladder

Published: Mar 25, 2022 | Tags: Medtronic, TITAN 2 Study, Implantable Tibial Neuromodulation Device, Overactive Bladder

Jazz Reports the First Patient Enrollment in the P-II (EMERGE-201) Basket Trial of Zepzelca (lurbinectedin) for Advanced or Metastatic Solid Tumors

Published: Mar 25, 2022 | Tags: Jazz, P-II, EMERGE-201, Basket Trial, Zepzelca, lurbinectedin, Solid Tumors

AstraZeneca's Evusheld Receives CHMP's Recommendation for Approval in the EU for the Pre-Exposure Prophylaxis of COVID-19 in the EU

Published: Mar 25, 2022 | Tags: AstraZeneca, Evusheld, Approval, EU, Pre-Exposure Prophylaxis, COVID-19

Halozyme Signs a Collaboration and License Agreement with Chugai for Enhanze Drug-Delivery Technology

Published: Mar 25, 2022 | Tags: Halozyme, Chugai, Enhanze, Drug-Delivery Technology

Pfizer’s Respiratory Syncytial Virus Vaccine (PF-06928316 or RSVpreF) Receives the US FDA’s Breakthrough Therapy Designation for RSV

Published: Mar 24, 2022 | Tags: Pfizer, Respiratory Syncytial Virus Vaccine, PF-06928316, RSVpreF, US, FDA, Breakthrough Therapy Designation, RSV

PharmaTher Reports Results of Ketamine in a Clinical Study for the Treatment of Parkinson’s Disease

Published: Mar 24, 2022 | Tags: PharmaTher, Ketamine, Parkinson’s Disease

argenx Reports Results of Vyvgart (efgartigimod alfa-fcab) in P-III (ADAPT-SC) Study for the Treatment of Generalized Myasthenia Gravis

Published: Mar 24, 2022 | Tags: argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADAPT-SC Study, Generalized Myasthenia Gravis

Silence Therapeutics and Mallinckrodt Submit Clinical Trial Application for SLN501 to Treat Complement-Mediated Diseases

Published: Mar 24, 2022 | Tags: Silence, Mallinckrodt, Clinical Trial Application, SLN501, Complement-Mediated Diseases

Moderna Reports Interim Results of COVID-19 Vaccine (mRNA-1273) in P-II/III (KidCOVE) Study for Children Aged 6 Months to Under 6 Years

Published: Mar 24, 2022 | Tags: Moderna, COVID-19 Vaccine, mRNA-1273, P-II/III, KidCOVE Study

Pfizer Reports Results of Etrasimod in P-III (ELEVATE 12) Trial for the Treatment of Ulcerative Colitis

Published: Mar 24, 2022 | Tags: Pfizer, Etrasimod, P-III, ELEVATE 12 Trial, Ulcerative Colitis

GSK Entered into a R&D Collaboration with LifeMine to Discover Novel Therapies for Multiple Disease

Published: Mar 23, 2022 | Tags: GSK, LifeMine, Avatar-Rx Platform, Multiple Disease

Palisade Bio Receives the US FDA’s Study May Proceed Letter for P-III Clinical Trial of LB1148 to Improved Bowel Function After Abdominal Surgery

Published: Mar 23, 2022 | Tags: Palisade Bio, US, FDA, P-III, Clinical Trial, LB1148, Bowel Function, Abdominal Surgery

Novavax and Serum Institute of India’s NVX-CoV2373 Receives the DCGI's EUA for the Treatment of COVID-19 in Adolescents Aged ≥12 to <18 Years in India

Published: Mar 23, 2022 | Tags: Novavax, Serum Institute of India, NVX-CoV2373, DCGI, EUA, COVID-19, India

Aligos Discontinues ALG-020572 in the (ALG-020572-401) Study for the Treatment of Chronic Hepatitis B

Published: Mar 23, 2022 | Tags: Aligos, ALG-020572, ALG-020572-401 Study, Chronic Hepatitis B

BioMarin’s Vimizin (elosulfase alfa) Receives NICE Recommendation for the Treatment of Mucopolysaccharidosis Type 4A

Published: Mar 23, 2022 | Tags: BioMarin, Vimizin, elosulfase alfa, NICE, Recommendation, Mucopolysaccharidosis Type 4A

ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

Published: Mar 23, 2022 | Tags: ObsEva, Linzagolix, P-III, EDELWEISS 3 Trial, Endometriosis-Associated Pain

Plus Therapeutics Reports First Patient Dosing in P-I/IIa (ReSPECT-LM) Dose Escalation Trial of 186RNL for Leptomeningeal Metastases

Published: Mar 22, 2022 | Tags: Plus Therapeutics P-I/IIa, ReSPECT-LM, Dose Escalation Trial, 186RNL, Leptomeningeal Metastases

GeNeuro Reports Results of Temelimab + Rituximab in P-II (ProTEct-MS) trial for the Treatment of Multiple Sclerosis

Published: Mar 22, 2022 | Tags: GeNeuro, Temelimab, Rituximab, P-II, ProTEct-MS Trial, Multiple Sclerosis

Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblastoma

Published: Mar 22, 2022 | Tags: Ascentage Pharma, Alrizomadlin, APG-115, US, FDA, Rare Pediatric Disease Designation, Neuroblastoma

uniQure Reports Completion of Patient Enrollment in the First Two Cohorts of P-I/II Trial for AMT-130 to Treat Huntington’s Disease

Published: Mar 22, 2022 | Tags: uniQure, P-I/II Trial, AMT-130, Huntington’s Disease

Tonix Reports Results of TNX-102 SL in P-III (RALLY) Study for the Treatment of Fibromyalgia

Published: Mar 22, 2022 | Tags: Tonix, TNX-102 SL, P-III, RALLY Study, Fibromyalgia

Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for the Treatment of MSI‑H/dMMR Advanced Endometrial Carcinoma

Published: Mar 22, 2022 | Tags: Merck, Keytruda, pembrolizumab, US, FDA, Approval, MSI‑H/dMMR, Endometrial Carcinoma

Nuance Pharma Signs a License and Supply Agreement with Bavarian Nordic to Develop and Commercialize of Respiratory Syncytial Virus Vaccine

Published: Mar 21, 2022 | Tags: Nuance Pharma, Bavarian Nordic, Respiratory Syncytial Virus Vaccine,

Scilex Reports Efficacy and Safety Results of Semdexa (SP-102) P-III (C.L.E.A.R.) Program for Sciatica Pain Management

Published: Mar 21, 2022 | Tags: Scilex, Semdexa, SP-102, P-III, C.L.E.A.R. Program, Sciatica Pain Management

BMS Collaborated with Volastra to Develop and Commercialize Novel Therapies for Cancer

Published: Mar 21, 2022 | Tags: BMS, Volastra, Therapies, Cancer, CINtech platform

Marinus’ Ztalmy (ganaxolone) Receives the US FDA’s Approval for the Treatment of CDKL5 Deficiency Disorder

Published: Mar 21, 2022 | Tags: Marinus, Ztalmy, ganaxolone, US, FDA, Approval, CDKL5 Deficiency Disorder

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-09) Trial for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression at ESMO 2022

Published: Mar 21, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-09 Trial, Stage IB-IIIA, NSCLC, PD-L1 Expression

BMS’ Opdualag (nivolumab and relatlimab-rmbw) Receives the US FDA’s Approval for the Treatment of Unresectable or Metastatic Melanoma

Published: Mar 21, 2022 | Tags: BMS, Opdualag, nivolumab, relatlimab-rmbw, US, FDA, Approval, Metastatic, Melanoma

Related Post: PharmaShots Weekly Snapshots (March 07-11, 2022)

 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions